Obesity Clinical Trials

Find Obesity Clinical Trials Near You

Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity

Status: Recruiting
Location: See all (40) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment participants get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. Possible side effects will be followed carefully during the study. For each participant, the study will last for about 1 year and 6 months.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study

• Female or male (sex at birth)

• Age 18 years or above at the time of signing the informed consent

• History of at least one self-reported unsuccessful dietary effort to lose body weight (a\*)

• Body mass index (BMI) greater than or equal to \>= 30.0 kilogram per square meter (kg/m\^2), or BMI greater than or equal to \>= 27.0 kg/m\^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease (a\*)

Locations
United States
California
Diablo Clinical Research, Inc.
RECRUITING
Walnut Creek
Colorado
Univ of Colorado at Denver
RECRUITING
Aurora
Florida
Florida Inst For Clin Res LLC
RECRUITING
Orlando
Oviedo Medical Research, LLC
RECRUITING
Oviedo
Illinois
Walgreens - Store 11760
RECRUITING
Oak Park
Indiana
Midwest Inst For Clin Res
RECRUITING
Indianapolis
Missouri
StudyMetrix Research LLC
RECRUITING
City Of Saint Peters
North Carolina
PharmQuest Life Sciences LLC
RECRUITING
Greensboro
Virginia
Selma Medical Associates
RECRUITING
Winchester
Other Locations
Argentina
CIPREC Pueyrredon
RECRUITING
Buenos Aires
CEDIC Centro de Investigación Clínica
RECRUITING
Caba
Australia
Sydney Cardiometabolic Centre
RECRUITING
Liverpool
Hunter Diabetes Centre
RECRUITING
Merewether
Canada
Nova Scotia Hlth Halifax
RECRUITING
Halifax
Hamilton Medical Rsrch Grp
RECRUITING
Hamilton
Wharton Med Clin Trials
RECRUITING
Hamilton
Milestone Research
RECRUITING
London
Centricity Research Mirabel
RECRUITING
Mirabel
G.A. Research Associates Ltd.
RECRUITING
Moncton
Centricity Research Oshawa
RECRUITING
Oshawa
Centricity Research Toronto
RECRUITING
Toronto
France
Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec
ACTIVE_NOT_RECRUITING
Saint-herblain
Centre de Recherche Clinique Portes Du Sud
ACTIVE_NOT_RECRUITING
Vénissieux
Germany
InnoDiab Forschung GmbH
ACTIVE_NOT_RECRUITING
Essen
Wendisch - Dahl Hamburg - DZHW
ACTIVE_NOT_RECRUITING
Hamburg
RED-Institut für medizinische Forschung und Fortbildung GmbH
ACTIVE_NOT_RECRUITING
Oldenburg In Holstein
Italy
A.O.U. Bologna_ Policlinico S.Orsola Malpighi
RECRUITING
Bologna
IRCCS Ospedale San Raffaele Milano
NOT_YET_RECRUITING
Milan
AOUP Giaccone Palermo
ACTIVE_NOT_RECRUITING
Palermo
Fondazione Policlinico Universitario Agostino Gemelli IRCS
ACTIVE_NOT_RECRUITING
Rome
Norway
Haukeland Universitetssykehus
RECRUITING
Bergen
Drammen sykehus - Vestre Viken HF
RECRUITING
Drammen
St. Olavs Hospital HF
RECRUITING
Trondheim
Poland
Osteo-Medic s.c. A. Racewicz, J. Supronik
RECRUITING
Bialystok
Care Clinic Sp. z o. o.
RECRUITING
Katowice
Terpa Sp. z o.o. Sp. k.
RECRUITING
Lublin
NBR Polska Tomasz Klodawski
RECRUITING
Warsaw
United Kingdom
Oak Tree Surgery
RECRUITING
Liskeard
North Coast Medical Ltd
RECRUITING
Newquay
Brunel Medical Practice
RECRUITING
Torquay
Contact Information
Primary
Novo Nordisk
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Time Frame
Start Date: 2025-11-05
Estimated Completion Date: 2027-07-14
Participants
Target number of participants: 300
Treatments
Experimental: Cagrilintide
Participants will receive cagrilintide subcutaneously once weekly for 64 weeks.
Placebo_comparator: Placebo
Participants will receive placebo matched to cagrilintide subcutaneously once weekly for 64 weeks.
Related Therapeutic Areas
Sponsors
Leads: Novo Nordisk A/S

This content was sourced from clinicaltrials.gov